Nuvation Bio (NYSE:NUVB – Get Rating) and Immunome (NASDAQ:IMNM – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Earnings & Valuation
This table compares Nuvation Bio and Immunome’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvation Bio | N/A | N/A | -$104.20 million | ($0.48) | -3.54 |
| Immunome | N/A | N/A | -$36.90 million | ($2.48) | -1.92 |
Nuvation Bio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Nuvation Bio | N/A | -15.75% | -15.30% |
| Immunome | N/A | -140.75% | -83.30% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Nuvation Bio and Immunome, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvation Bio | 0 | 3 | 3 | 0 | 2.50 |
| Immunome | 0 | 0 | 2 | 0 | 3.00 |
Nuvation Bio currently has a consensus price target of $4.00, indicating a potential upside of 135.29%. Immunome has a consensus price target of $8.00, indicating a potential upside of 68.42%. Given Nuvation Bio’s higher probable upside, research analysts clearly believe Nuvation Bio is more favorable than Immunome.
Insider & Institutional Ownership
64.9% of Nuvation Bio shares are owned by institutional investors. Comparatively, 19.7% of Immunome shares are owned by institutional investors. 36.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 17.5% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Nuvation Bio has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.
Summary
Nuvation Bio beats Immunome on 7 of the 11 factors compared between the two stocks.
About Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
About Immunome
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
